Islet Cell Antibody Screen with Reflex to Titer
Use
Measurement of autoantibodies against pancreatic islet cells—including GAD‑65, ICA‑512 (IA‑2), and insulin autoantibody—is a sensitive means to assess risk and predict the onset of type 1 diabetes; the number of positive antibodies and antibody titers correlate with the severity of the autoimmune process. This screen helps identify individuals with autoimmune-mediated β-cell destruction and can guide further diagnostic evaluation and monitoring.
Special Instructions
If the initial Islet Cell Antibody Screen is positive, an Islet Cell Antibody Titer is performed at an additional charge. Performing laboratory: Quest Diagnostics Nichols Institute, San Juan Capistrano, CA.
Limitations
Specimens showing gross hemolysis, lipemia, or icterus may cause erroneous results and are rejected. Fasting specimen preferred, but not strictly required. The test has not been reviewed or cleared by the FDA; it is a laboratory-developed test validated under CLIA.
Methodology
Immunoassay (Immunofluorescence Assay (IFA))
Biomarkers
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL serum
Minimum Volume
0.5 mL serum
Container
Gold‑top SST (or red‑top plain tube)
Collection Instructions
Let specimen clot 30–60 minutes then centrifuge; transfer serum to transport tube.
Patient Preparation
Fasting specimen is preferred.
Causes for Rejection
Gross hemolysis; grossly lipemic; grossly icteric
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 14 days |
| Frozen | 6 months |